Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings

Current Opinion in Oncology

Volumn 24, Issue 5, 2012, Pages 522-530

  Semeere, Aggrey S ^a,b   Busakhala, Naftali ^c   Martin, Jeffrey N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Infectious Diseases Institute   (Uganda)

^c MOI UNIVERSITY   (Kenya)

Author keywords

antiretroviral therapy; HIV AIDS; incidence; Kaposi's sarcoma; resource limited settings

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER INCIDENCE; CANCER REGISTRY; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFORMATION RETRIEVAL; KAPOSI SARCOMA; MEDLINE; POPULATION RESEARCH; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; RISK ASSESSMENT; THERAPY EFFECT;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; INCIDENCE; SARCOMA, KAPOSI;

EID: 84865508063     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328355e14b     Document Type: Review

References (46)

1. Hymes KB, Cheung T, Greene JB, et al. Kaposi's sarcoma in homosexual mena report of eight cases. Lancet 1981; 2:598-600. (Pubitemid 11051872)
2. Hoover DR, Black C, Jacobson LP, et al. Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men. Am J Epidemiol 1993; 138:266-278. (Pubitemid 23263597)
3. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-1991: changes in incidence in the era of AIDS. Int J Cancer 1993; 54:26-36. (Pubitemid 23136995)
4. Zwahlen M, Harris R, May M, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
5. GLOBAL HIV/AIDS RESPONSE: Epidemic update and health sector response towards Universal Access. Geneva, Switzerland: WHO/UNAIDS/UNICEF 2011; 30 November 2011.
6. Fairall LR, Bachmann MO, Louwagie GM, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168:86-93.
7. Carrieri MP, Pradier C, Piselli P, et al. Reduced incidence of Kaposi's sarcoma and of systemic nonhodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer 2003; 103:142-144. (Pubitemid 35424220)
8. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432. (Pubitemid 40528605)
9. Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800-804.
10. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-2226. (Pubitemid 30002965)
11. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 1999; 319:23-24. (Pubitemid 29304340)
12. Lodi S,Guiguet M, Costagliola D, et al. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst 2010; 102:784-792.
13. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 2000; 356:291-296. (Pubitemid 30459587)
14. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736. (Pubitemid 351717418)
15. Pipkin S, Scheer S, Okeigwe I, et al. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. AIDS 2011; 25:463-471.
16. Asiimwe F, Moore D, Were W, et al. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. HIV Med 2012; 13:166-171.
17. Bohlius J, Valeri F, Maskew M, et al. Incidence of Kaposi's sarcoma in HIV-infected patients: a prospective multi-cohort study from Southern Africa. 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI); Bethesda, Maryland; 7-8 November 2011.
18. Martin J, Wenger M, Busakhala N, et al. Prospective evaluation of the impact of potent antiretroviral therapy on the incidence of Kaposi's Sarcoma in East Africa: findings from the International Epidemiological Databases to Evaluate AIDS (IeDEA) Consortium. 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI); Bethesda, Maryland; 7-8 November 2011.
19. Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357:1352-1353. (Pubitemid 47481472)
20. Chan J, Kravcik S, Angel JB. Development of Kaposi's sarcoma despite sustained suppression of HIV plasma viremia. J Acquir Immune Defic Syndr 1999; 22:209-210.
21. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957-1963. (Pubitemid 47329772)
22. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560. (Pubitemid 30660034)
23. Dal Maso L, Polesel J, Serraino D, et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100:840-847.
24. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
25. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103:416-422.
26. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010; 170:1337-1345.
27. Chaturvedi AK, Mbulaiteye SM, Engels EA. Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. Ann Epidemiol 2008; 18:230-234.
28. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972. (Pubitemid 47073502)
29. Polesel J, Franceschi S, Suligoi B, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer 2010; 127:1437-1445.
30. Msyamboza KP, Dzamalala C, Mdokwe C, et al. Burden of cancer in Malawi; common types, incidence and trends: National population-based cancer registry. BMC Res Notes 2012; 5:149.
31. Grulich AE, Li Y, McDonald AM, et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination antiretroviral therapy. AIDS 2001; 15:629-633. (Pubitemid 32281359)
32. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011; 117:1089-1096.
33. Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39:1380-1384. (Pubitemid 39458526)
34. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11:1731-1738. (Pubitemid 27470275)
35. Crum-Cianflone NF, Hullsiek KH, Ganesan A, et al. Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic? AIDS 2010; 24:2881-2883.
36. Gingues S, Gill MJ. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. HIV Med 2006; 7:369-377. (Pubitemid 44123247)
37. Hessol NA, Seaberg EC, Preston-Martin S, et al. Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr 2004; 36:978-985. (Pubitemid 38949847)
38. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
39. Jones JL, Hanson DL, Dworkin MS, Jaffe HW. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 24:270-274.
40. Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22:489-496. (Pubitemid 351317290)
41. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on nonnucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17:F17-F22. (Pubitemid 36951678)
42. Seaberg EC, Wiley D, Martinez-Maza O, et al. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010; 116:5507-5516.
43. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985-990. (Pubitemid 43157675)
44. International Epidemiologic Databases to Evaluate AIDS.2011. http://iedea. org/whoweare. [Accessed 14 September 2011]
45. Somdyala NI, Bradshaw D, Gelderblom WC, Parkin DM. Cancer incidence in a rural population of South Africa, 1998-2002. Int J Cancer 2010; 127:2420-2429.
46. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer 2010; 126:1187-1195.